Clotbusting On The Clock: New Brands Must Establish Themselves Before Improved Plavix Diagnostics Do
FDA's three-month postponement of a decision on AstraZeneca PLC’s NDA for Brilinta (ticagrelor) may signal more trouble for the long-term viability of the product rather than any concern about its actual approvability.
You may also be interested in...
AstraZeneca's Brilique Approved In The EU
AstraZeneca's antiplatelet agent Brilique/Brilinta receives its first approval, but pricing negotiations will delay launch in most countries.
GRAVITAS Fails To Show Clinical Value Of Platelet Function Testing For Plavix
Study results don't prove clinical benefit for point-of-care testing, but trial may not have been sufficiently powered to show a difference.
AstraZeneca's Ticagrelor Gets Positive EU Recommendation, But FDA Could Catch Up Soon
Europe's CHMP recommends ticagrelor for patients with acute coronary syndromes, while FDA still grapples with lack of effect in North American patients.